Phaseline

Companies › Beijing Baylx Biotech

Beijing Baylx Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BC-U001
Human umbilical cord-derived mesenchymal stem cells (hUC-MSC) with anti-inflammatory and i
–Phase 1Rheumatoid Arthritis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04971980BC-U001Phase 1Rheumatoid ArthritisImmunologyJul 2023

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.